InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（7 笔）
内部人交易记录
首席财务官已披露买入
1
已披露卖出
7
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the detailed record of transactions filed by Dier Mardi, 首席财务官. Director active across 5 companies, notably Adamas Pharmaceuticals Inc. Cumulatively, 14 disclosures have been published. Split: 1 buy · 7 sells. Total volume traded: €1.5m. Activity tracked since 2 June 2021. The latest transaction was disclosed on 4 March 2026 (Attribution). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Dier Mardi
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报14 总计
5,215 股0Common StockSEC:0001628280-26-015775:0
1,183 股@ US$427.2124.1% 占其流量Common StockSEC:0001628280-26-013394:0
4,173 股@ US$251.6366.9% 占其流量Common StockSEC:0001628280-25-055164:0
258 股@ US$323.0417.1% 占其流量Common StockSEC:0001628280-25-012369:0
3,784 股0Common StockSEC:0001628280-25-011407:0
1,187 股@ US$325.8982.9% 占其流量Common StockSEC:0001628280-25-010508:0
5,556 股@ US$18.00100.0% 占其流量Common StockSEC:0001209191-23-028864:0
标准退出：2023年8月7日 (T+90)
1,629 股@ US$40.169.1% 占其流量Common StockSEC:0001209191-22-053884:0
3,484 股@ US$38.2218.7% 占其流量Common StockSEC:0001209191-22-053647:0
20,000 股0Common StockSEC:0001209191-22-050670:0
534 股@ US$66.626.5% 占其流量Common StockSEC:0001209191-22-015833:0
3,477 股@ US$82.7951.4% 占其流量Common StockSEC:0001209191-21-060504:0
5,000 股0Common StockSEC:0001328143-21-000056:0
13,750 股Common StockSEC:0001209191-16-094212:0
14 条申报中的 14 条
About Dier Mardi
Dier Mardi is Chief Financial Officer and has reported 14 filings in total. Across the 14 sampled filings, the activity spans 2016-01-29 to 2026-03-06, with EUR 91,209 of buys and EUR 1,363,518 of sells, and the most frequent transaction type is Sale. The filings involve Madrigal Pharmaceuticals, INC., Ultragenyx Pharmaceutical Inc., ACELYRIN, Inc., Adamas Pharmaceuticals Inc and PORTOLA PHARMACEUTICALS INC.
